The development of new peptide drugs in my country is the key to overcome technical and equipment problems

[editor's point of view of chinapharma.com] recently, the 4th global peptide R & D conference, jointly sponsored by Hangzhou Economic and Technological Development Zone and China peptide Biochemical Co., Ltd., kicked off This meeting attracted the participation of famous peptide drug R & D enterprises, peptide experts from famous universities, experts from China US drug administration, USP and world famous venture capital institutions in the field of biopharmaceutical industry In recent years, the development, production, quality and regulation of peptide drugs have been discussed intensively It is understood that polypeptide drugs are composed of amino acids, the metabolites of which are also amino acids, which are essential elements of human body Therefore, the polypeptide drugs have low toxicity and high safety At present, the global peptide drug market has exceeded 20 billion US dollars, with more than 80 kinds of peptide drugs Chronic disease treatment accounts for more than 75% of the global peptide drug market, and it is also the core market of peptide drugs Especially in the context of China's aging society and the continuous improvement of the health care level of the whole people, the advantages of peptide drugs are more and more obvious There are huge market opportunities for peptide drugs In recent years, the research and development of peptide drugs in China has also shown a promising development situation, and new drugs have been emerging and approved for production However, the development of peptide drugs in China lags behind the developed countries in general, and the proportion of relevant projects is less than 5% of the major new drug development projects in China Due to the limitation of process, equipment and technology, there are few enterprises with the ability of large-scale production of chemical synthetic peptide drugs in China The peptide drug industry is still in the supplier market, and the market competition is relatively relaxed In China, peptide drug production is not only difficult to scale, but also low quality It is reported that at present, more than 30 peptide drugs produced and sold by Chinese pharmaceutical enterprises are basically generic drugs and APIs, and the active ingredients extracted from natural substances are the main ones, with large pollution, low added value and unstable quality However, unlike China, in recent years, the mainstream peptide drugs in the world are synthetic or structural modified, which not only have uniform composition and stable quality, but also have less pollution and high efficiency in the production process Synthetic polypeptide drugs are the hot spot of market development at present, but synthetic technology also puts forward higher requirements for pharmaceutical enterprises, which requires strict quality control, stable synthesis, separation and purification process In this regard, China needs to learn lessons, continue to strengthen independent innovation, promote the construction of key technology platforms, and use modern biotechnology to produce peptide drugs In addition, great efforts have been made in the synthesis, separation and purification process to promote the continuous improvement of relevant technologies and equipment At present, peptide drugs in China are mainly foreign brands, and foreign products occupy a large market share in peptide drugs market in China Our country should further strengthen the research and development of peptide drugs, strive to form style and advantage, make brand internationally, and gradually expand the share of local peptide drugs in the international market At the same time, we should increase investment in basic research, strengthen the training and introduction of talents, attach importance to and support the combination of production, learning and research, and speed up the transformation process of scientific research results industry Nowadays, peptide drugs have become the mainstream of drug development In China, we should not only make great efforts in peptide drug production, but also in drug delivery, we need to continue to strengthen innovation and strive to develop new peptide drug delivery equipment It is reported that the molecular weight of polypeptide drugs is far greater than that of traditional small molecule drugs, and the biological activity and structure are closely related, so the way of administration is still mainly subcutaneous injection However, on the one hand, this method greatly increases the discomfort of patients, resulting in low compliance of patients; on the other hand, it also leads to the improvement of clinical expenses The way of drug delivery has become one of the bottlenecks restricting the development of peptide drugs In order to compete for the market of peptide drugs in China, it is not only necessary to strengthen the innovation of related technologies and equipment, improve the production capacity of peptide drugs, but also in the aspect of drug delivery, Chinese enterprises need to make great efforts to overcome various difficulties, develop more convenient delivery equipment and find better ones Method of administration (source: China Pharmaceutical network)